Advanced glycosylation end-products and the pathogenesis of accelerated atherosclerosis in diabetes;I prodotti di glicosilazione ayanzata e la patogenesi dell'aterosclerosi accelerata nel diabete

Giornale Italiano di Cardiologia

Volumn 26, Issue 7, 1996, Pages 699-719

  Basta, Giuseppina ^a   De Caterina, Raffaele ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b CNR   (Italy)

Author keywords

Advanced glycosylation end products (AGE); Atherosclerosis; Diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ARTERIOSCLEROSIS; BIOSYNTHESIS; BLOOD CLOTTING DISORDER; CELL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DIABETIC ANGIOPATHY; HUMAN; LIPID METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW;

ARTERIOSCLEROSIS; BLOOD COAGULATION DISORDERS; CELL MEMBRANE PERMEABILITY; CELLS; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID METABOLISM; OXIDATION-REDUCTION;

EID: 0030159245     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Colwell JA, Lopes-Virella MF: A review of the development of large vessel disease in diabetes mellitus. Am J Med 1988; 85 (Suppl 5A): 113-118.
2. Beach KW, Strandness DE: Atherosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin dependent diabetes. Diabetes 1981; 29: 882-888.
3. Jørgensen KD, Brinchmann-Hansen O, Bangstad HJ, Hanssen KF: Blood glucose control and microvascular complications - what do we do now? Diabetologia 1994; 37: 1172-1177.
4. Shurtleff D: Some characteristics related to incidence of cardiovascular disease and death: Framingham Study 18- year follow-up. Washington DC Government Printing Office, 1974.
5. Butler WJ, Ostrander L Jr, Carman WJ, Lam- phiear DE: Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985; 121: 541-547.
6. Barrett-Connor E, Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983; 118: 489-496.
7. Pan WH, Cedres LB, Liu K et al: Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986; 123: 504-516.
8. Krolewski AS, Kosinski EJ, Warrant JH et al: Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.
9. Robertson WB, Strong JP: Atherosclerosis in persons with hypertension and Diabetes Mellitus. Lab Invest 1968; 18: 538-551.
10. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 1984; 4: 323-340.
11. Ross R: The pathogenesis of atherosclerosis - an update. New Engl J Med 1986; 314: 488-500.
12. Masuda J, Ross R: Atherogenesis during low level hypercholesterolemia in the nonhuman primate I. Fatty streak formation. Arteriosclerosis 1990; 10: 164-177.
13. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM: Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992; 15: 1156-1167.
14. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
15. Gimbrone MA Jr: Endothelial dysfunction and the pathogenesis of atherosclerosis. In: Fidge N, Nestel P (eds): Atherosclerosis VII. New York, Elsevier Science Publishers, 1986; 367-369.
16. Gimbrone MA Jr, Bevilacqua MP: Vascular Endothelium: functional modulation at the blood interface. In: Simionescu N, Simionescu M: Endothelial cell biology in health and disease. New York, Plenum Press, 1988; 255-273.
17. Gimbrone MA Jr, Kume N, Cybulsky MI: Vascular endothelial dysfunction and the pathogenesis of atherosclerosis. Atherosclerosis Reviews 1996 (in press).
18. Gimbrone MA Jr: Vascular endothelium in health and disease. Molecular Cardiovascular Medicine 1996; (in press).
19. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: An epidemiologic view. Diabetes metab Rev 1987; 3: 463-524.
20. Beswick HT: Aldehydes or dicarbonyls in non enzymic glycosylation of proteins. Biochem J 1985; 226: 385-389.
21. Brownlee M, Vlassara H, Cerami A: The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In: Crabbe MJC (ed): Diabetic complications: Scientific and clinical aspects. London, Churchill Livingston, 1987.
22. Vlassara H, Fuh H, Makita Z, Krungkrai, Cerami A, Bucala R: Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-12047.
23. Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation, of hemoglobin. J Biol Chem 1981; 256: 5204-5208.
24. Mottensen HB, Christophersen C: Glucosylation of human haemoglobin in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin Alc. Clinica Chimica Acta 1983; 134: 317-326.
25. Koeníg RJ, Blobstein SH, Cerami A: Structure of carbohydrate of hemoglobin AIc. J Biol Chem 1977; 252: 2992-2997.
26. Larsen ML, Hørder M, Mogensen EF: Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1021-1025.
27. Poagor S, Ulrich PC, Benesath FA, Cerami A: Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA 1984; 81: 2684-2688.
28. Farmar J, Ulrich P, Cerami A: Novel pyrroles from sulfite-inhibited Maillard reactions, insight into the mechanism of inhibition. J Org Chem 1988; 53: 2346.
29. ε-(carboxymethyl)-lysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894.
30. ε-lysino)-lactic acid from model compounds and glycated proteins. J Biol Chem 1988; 263: 8816-8821.
31. Nakayama H, Teneda, S, Kuwajima S et al: Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989; 162: 740-745.
32. Makita Z, Vlassara H, Cerami A, Bukala R: Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 1992; 267: 5133-5138.
33. Makita Z, Vlassara H, Rayfield E et al: Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651-653.
34. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: Pathway for lipid oxi- dation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-6438.
35. Vlassara H, Bucala R, Striker L: Pathogenic effect of advanced glycosyktion: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70 (2): 138-151.
36. Collins T: Endothelial nuclear factor-xB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68: 499-508.
37. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-28.
38. Vishwanath V, Frank KE, Elmmets CA, Dauchot PJ, Monnier VM: Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 1986; 35: 916-921.
39. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408.
40. Oimomi M, Maeda Y, Baba S, Iga T: Relationship between levels of advanced-stage products of the Maillard reaction and the development of diabetic retinopathy. Exp Eye Res 1989; 49: 317-320.
41. Sell DR, Monnier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380-384.
42. Fujimori E: Cross-linking and fluorescence changes of collagen by glycation and oxidation. Biochim Biophys Acta 1989; 998: 105-110.
43. Wickens DG, Norden AG, Lunec J, Dormandy TL: Fluorescence changes in human gamma globulin induced by free radical activity. Biochim Biophys Acta 1983; 742: 607-616.
44. Jones AF, Lunec J: Protein fluorescence and its relationship to free radical activity. Br J Cancer 1987; 56 (Suppl VII): 60-65.
45. Smith EB, Massie IB, Alexander KM: The release of an immobilized lipoprotein fraction from atherosclerotic lesions by incubation with plasmin. Atherosclerosis 1976; 25: 71-84.
46. Brownlee M, Pongor S, Cerami A: Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the in situ formation of immune complexes. J Exp Med 1983; 158: 1739-1744.
47. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosylation products on collagen covalently trap low density lipoprotein. Diabetes 1985; 34: 938-941.
48. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
49. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261.
50. Dybdahl H, Ledet TS: Diabetic macroangiopathy. Quantitative histopathological studies of the extramural coronary arteries from Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1987; 30: 882-886.
51. Iberg N, Fluckiger R: Non-enzymatic glycosylation of albumin in vivo. J Biol Chem 1986; 261: 13542-13545.
52. Yurchenco PD, Tsilibary EC, Charonis AS: Models for the self-assembly of basement membrane. J Histochem Cytochem 1986; 34; 93-102.
53. Eble AS, Thorpe SR, Baynes JW: Nonenzymatic glycosylation and glucose-dependent cross-linking of proteins. J Biol Chem 1983; 258: 9406-9412.
54. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994; 334: 793-795.
55. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 77: 333-337.
56. Sparrow CP, Parthasarathy S, Steinberg DJ: A macrophage receptor that recognized oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem 1989; 264: 2599-2604.
57. Frei B, Stocker R, Ames BN: Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988; 85: 9748-9752.
58. Morel DW, Chisolm GM: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 1989; 30: 1827-1834.
59. Brazg R, Duell PB, Gilmore M, Bierman EL, Chait A: Effects of dietary antioxidants on LDL oxidation in noninsulin-dependent diabetes (Abstract). Clin Res 1992; 40: 103.
60. Stankova R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Plasma ascorbate concentrations and blood cell dehydroascorbate transport in patients with diabetes mellitus. Metabolism 1984; 33: 347-353.
61. Bucala R, Cerami A: Phospholipids react with glucose to initiate advanced glycosylation and fatty acid oxidation: inhibition of lipid advanced glycosylation and oxidation by aminoguanidine. Diabetes 1992; 41 (23A): 91.
62. Picard S, Parthasarathy S, Fruebis J, Witztum JL: Aminoguanidine inhibits oxidative modification of low density lipiprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1991; 89: 6876-6880.
63. Colwell JA: Vascular thrombosis in Type II diabetes mellitus. Diabetes 1993; 42: 8-11.
64. Jones RL: Fibrinopeptide A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 1985; 34: 836-841.
65. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R: Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989; 38: 1162-1163.
66. Villanueva GB, Allen N: Demonstration of altered antithrombin III activity due to non enzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes 1988; 37: 1103-1107.
67. Gray E, Barrowcliffe TW: Inhibition of antithrombin III by lipid peroxides. Thromb Res 1985; 37: 241-250.
68. Vukovich TC, Schernthaner G: Decreased protein C levels in patients with insulin- dependent type I diabetes mellitus. Diabetes 1986; 35: 617-619.
69. Davis JW, Hartman CR, Davis RF, Kyner JL, Lewis HD, Phillips PE: Platelet aggregate ratio in diabetes mellitus. Acta Haemat 1982: 67: 222-224.
70. Davì G, Rini GB, Averna M: Enhanced platelet release reaction in insulin- dependent and insulin-indipendent diabetic patients. Haemostasis 1982; 12: 275-281.
71. Sampietro T, Lenzi S, Cecchetti P: Nonenzymatic glycation of human platelet membrane proteins in vitro and in vivo. Clin Chem 1986; 32: 1328-1331.
72. Yatscoff RW, Mehta A, Gerraed JM: Glycation of platelet protein in diabetes mellitus: lack of correlation with platelet function. Clin Biochem 1987; 20: 359-363.
73. Winocour PD, Watala C, Kinlough-Rathbone RI: Reduced membrane fluidity and increased glycation of membrane proteins of platelets from diabetic subjects are not associated with increased platelet adherence to glycated collagen. J Lab Clin Med 1992; 120: 921-928.
74. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF: Enhancement of platelet aggregation by low density lipoproteins from IDDM patients. Diabetes 1988; 37: 1652-1657.
75. Davi G, Catalano I, Averna M et al: Thromboxane biosynthesis and platelet function in type II Diabetes mellitus. N Engl J Med 1990; 322: 1769-1774.
76. Yang Z, Makita J, Mori Y et al: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174: 515-524.
77. Brett J, Schmidt AM, Yan SD et al: Survey of the distribution of a newly characterized receptor for advanced glycation endproducts in tissues. Am J Pathol 1993; 143: 1699-1712.
78. Schmidt AM, Hori O, Brett J, Yan SD, Wautier J-L, Stern D: Cellular receptors for advanced glycation end products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscher Thromb 1994; 14: 1521-1528.
79. Neeper M, Schmidt AM, Brett J et al: Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem 1992; 267: 14998-15004.
80. Vlassara H, Brownlee M, Cerami A: Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164: 1301-1309.
81. Schmidt AM, Hasu M, Popov D et al: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE-proteins. Proc Natl Acad Sci USA 1994; 91: 8807-8811.
82. Schmidt AM, Mora R, Cao R et al: The endothelial cell binding site for advanced glycation endproducts consists of a complex of an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1994; 269: 9882-9888.
83. Schmidt AM, Vianna M, Gerlach M et al: Isolation and characterization of binding proteins for advanced glycation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
84. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A: Advanced glycosylation products on erythrocyte cell surface induce receptor mediated phagocytosis by macrophages; a model of turnover of aging cells. J Exp Med 1987; 166: 539-549.
85. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87: 9010-9014.
86. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose- modified proteins: role in normal tissue remodeling. Science 1988; 240: 1546-1548.
87. Le J, Weinstein D, Gubler U, Vilcek J: Induction of membrane-associated interleukin 1 by tumor necrosis factor in human fibroblasts. J Immunol 1987; 138: 2137-2140.
88. Kirstein M, Aston C, Hintz R, Vlassara H: Receptor-specific induction of insulin-like growth factor I (IGF-1) in human monocytes by advanced glycosylation and product-modified proteins. J Clin Invest 1992; 90: 439-446.
89. Vlassara H, Brownlee M, Gerami A: Specific macrophage receptor activity for advanced glycosylation endproducts inversely correlates with insulin levels in vivo. Diabetes 1988; 37: 456-461.
90. Vlassara H, Moldawer L, Chan B: Macrophage/monocyte receptor for nonenzymatically glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. J Clin Invest 1989; 84: 1813-1820.
91. Horii Y, Skolnik E, Suthanthiran M, Vlassara H: Novel T-cell receptors for advanced glycation end- products (AGE) mediate production of IFN (Abstract). Diabetes 1992; 41 (59).
92. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
93. Stemme S, Rymo L, Hansson GK: Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest 1991; 65: 654-660.
94. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H: Endothelial receptor-mediated binding of glucose- modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-1407.
95. Frield HP, Till GO, Ryan US, Ward P : Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J 1989; 3: 2512-2518.
96. Suzuki Y, Wang W, Vu TH, Raffin TA: Effect of NADPH oxidase inhibition endothelial cell ELAM-1 mRNA expression. Biochem Biophys Res Commun 1992; 184: 1339-1343.
97. Van Hindsberg VWM, Kooistra T, Van Den Berg EA, Princen HMG, Fiers W, Emeis JJ: Tumour necrosis factor increases the production of plasminogen activator in vivo and in cultured endothelial cells. Blood 1988; 72: 1467-1473.
98. Emeis JJ, Kooistra T: Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266.
99. Bucala R, Tracey J, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
100. De Caterina R, Libby P, Peng H-B et al: Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest 1995; 96: 60-68.
101. De Caterina R, Shin WS, Liao JK, Libby P: Nitric oxide inhibits cytokine-induced expression of endothelial leukocyte adhesion molecules (Abstract). Circulation 1994; 90 (4): 1-29.
102. Oyama Y, Kawasaki H, Hattori Y, Kanno M: Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986; 131: 75-78.
103. Brink C, Duncan PG, Douglas JS: Decreased vascular sensitivity to histamine during aging. Agens Actions 1984; 14: 8-10.
104. Ludmer PL, Selwyn A, Shook TL et al: Paradoxical vasoconstriction produced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.
105. Panza JA, Quyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patient with essential hypertension. N Engl J Med 1990; 323: 22-27.
106. Bevilacqua MP, Stengelin S, Gimbrone MAJr, Seed B: Endothelial leukocyte adhesion molecule 1: an in- ducible receptor for neutrophils related to complement regulatory proteins and lectins. Science (Washington) 1989; 243: 1160-1165.
107. Simmons D, Makgoba MW, Seed B: ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature (London) 1988; 331: 624-627.
108. Osborn L, Hession C, Tizard R, et al: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-1211.
109. Cybulsky MI, Gimbrone MAJr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791.
110. Baeuerle PA: The inducible transcription activator NF-kB: regulation by distinct protein subunits. Biochim Biophys Acta 1991; 1072: 63-80.
111. Lenardo MJ, Baltimore D: NF-xB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1988; 58: 227-229.
112. Baeuerle PA, Henkel T: Function and activation of NF-xB in the immune system. Annu Rev Immunol 1994; 12: 141-179.
113. Mullarkey C, Edelstein D, Btownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-939.
114. 2-generation and lipid peroxidation during the oxidation of a glycated polypeptide, glycated polylysine, in the presence of iron-ADP. Biochim Biophys Acta 1990; 1043: 27-33.
115. Yan SD, Schmidt AM, Anderson GM et al: Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
116. Wautier JL, Wautier MP, Schmidt AM et al: Advanced glycation end products (AGEs) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742-7746.
117. Rosenfield M, Paliaski W, Yla-Herttuala S, Butler S, Witztum J: Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying seventy from WHHL rabbits. Atherosclerosis 1990; 10: 336-349.
118. Schmidt AM, Zhang JH, Ctandall J et al: Interaction of advanced glycation end-products (AGEs) with their endothelial cell receptor (EC) leads to enhanced expression of VCAM-1: a mechanism for augmented monocyte-vessel wall interactions in diabetes (Abstract). FASEB J 1994; 8 (pt II): 3841.
119. De Caterina R, Cybulsky ML, Gimbrone MA Jr, Clinton SK, Libby P: Docosahexaenoic acid and expression of endothelial leukocyte adhesion molecules (Abstract). Circulation 1993; 88: 1-77.
120. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MAJr, Libby P: The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscl Thromb 1994; 14: 1829-1836.
121. De Caterina R, Nakagawa T, Hauptman PJ, Tanaka H: Cyclosporin-A vehicle inhibits basal Vascular Cell Adhesion Molecule-1 in coronary artery endothelium and cultured endothelial cells (Abstract). Circulation 1994; 90 (4 pt 2): 1-83.
122. De Caterina R, Tanaka H, Nakagawa T, Hauptman PJ, Libby P: The direct effect of injectable cyclosporine and its vehicle cremophor on endothelial VCAM-1 expression. Transplantation 1995; 60: 270-275.